Temasek-backed Tessa Therapeutics inks $120m oncology JV with China’s CSGKC

A research technologist prepares a Tessa Therapeutics Pte. virus specific t-cells (VST) infusion for cancer patients as part of a clinical trial inside a good manufacturing practice (GMP) room at Singapore's National Cancer Center (NCCS) in Singapore, on Thursday, Feb 23, 2017. Photographer: Nicky Loh/Bloomberg

Tessa Therapeutics, a Temasek-backed clinical stage biotech company, is forming a $120 million joint venture (JV) with China-Singapore Guangzhou Knowledge City (CSGKC) to find the next cure for cancer.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe

Contact us for corporate subscriptions at subs@dealstreetasia.com.